VPL introduces aid for inflammatory conditions
Veterinary Products Laboratories (VPL) launched an aid for equine inflammatory conditions at the American Association of Equine Practitioners annual conference
Veterinary Products Laboratories (VPL) launched an aid for equine inflammatory conditions at the American Association of Equine Practitioners annual conference, Nov. 21-25 in New Orleans. The product, Duralactin Equine, contains the proprietary ingredient called MicroLactin, and follows the successful launch in January 2003 of Duralactin Canine.The development of an equine product containing the biological response modifier in Duralactin is very exciting and represents a unique approach to aiding in the control of inflammatory conditions at the cellular level versus enzymatic level, says Dr. Craig Woods, MS, MBA, vice president of business development for VPL.He adds, We are offering the veterinarian a new alternative to NSAIDs and steroids with a product that modifies leukocyte trafficking, and which is backed by peer-reviewed studies in human and veterinary journals.Contrary to many NSAIDs, Duralactin has demonstrated no hepatic, renal or gastrointestinal toxicity, according to VPL. Duralactin Equine is not a drug or steroid, but a milk-derived product that works differently from NSAIDs or steroids. It is a vanilla-flavored granule packaged in an 850-gram bucket. The recommended dose is two level scoops mixed with feed daily. Each scoop provides 7,000 mg of microlactin.
For fastest response call (888) 241-9545 or visit the Web site at www.vpl.com.